drugset
drugset / Trial / NCT06137573

Human Mass Balance and Biotransformation Study of [14C]TNP-2198

NCT06137573 ↗

Phase 1 Completed 6 enrolled TenNor Therapeutics Inc.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to analyze absorption, metabolism, excretion, mass balance and biotransformation after a single oral dose of \[14C\]TNP-2198 in healthy male participants

Timeline

Start
2022-07-12
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifasutenizol Small molecule 600 mg Oral

Indications

Helicobacter pylori infectious disease